|
The Indian government has issued a notification banning Bextra (Valdecoxip) one of Pfizers best selling drugs, rnonths after the US Food & Drug Administration (USFDA) ordered its withdrawal due to concerns of serious, unpredictable and potentially life threatening skin reactions including death in patients. According to reports, there were over 155 reports of adverse reactions to Bextra, which was commonly used to relieve pain and inflammation from arthritis, worldwide. Bextra had sales of $1.4bn last year. Following the USFDAs orders to Pfizer, the Drugs Controller General of India (DCGI), started its own process of reviewing the drug. |
|
|
|
|
| Posted : 8/22/2005 |
|
|
|
|
